# AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia

> **NCT00512252** · PHASE1,PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 52 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** AMD3100
- **DRUG:** Mitoxantrone
- **DRUG:** Etoposide
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT00512252
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2016-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00512252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00512252, "AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00512252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*